Biotechnology firm Oryzon, a CataloniaBio & HealthTech member, has appointed Dutch executive Torsten Hoffmann to its management team as Global R&D Director replacing Tamara Maes.
Hoffmann holds a PhD in Chemistry from ETH Zürich and has over 20 years of experience leading drug research and development at Roche, Zealand Pharma, Silence Therapeutics and Taros Chemicals.
Tamara Maes will continue as vice-president of the Oryzon Board of Directors and president of its Scientific Advisory Board, a body that is to be strengthened with prestigious new international incorporations. Since the company was founded in 2000, Maes has been instrumental in discovering and developing novel epigenetic medicines to treat cancer and CNS diseases, two of which are now in Phase II clinical trials.
The company’s clinical development strategy continues unchanged.
Comments